Carla C Heise from Nipomo, CA, age 68

Us Patents

Inhibition Of Fgfr3 And Treatment Of Multiple Myeloma
view source
US Patent:

7825132, Nov 2, 2010
Filed:

Nov 5, 2004
Appl. No.:

10/983174
Inventors:

Shaopei Cai - Seattle WA, US
Joyce Chou - El Cerrito CA, US
Eric Harwood - Seattle WA, US
Carla C. Heise - Benicia CA, US
Timothy D. Machajewski - Martinez CA, US
David Ryckman - Bellevue WA, US
Xiao Shang - Bellevue WA, US
Marion Wiesmann - Brisbane CA, US
Shuguang Zhu - Shoreline WA, US
Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA
International Classification:

A61K 31/47
A01N 43/40
US Classification:

514314
Abstract:

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.

Modulating And Measuring Cellular Adhesion
view source
US Patent:

7875624, Jan 25, 2011
Filed:

Feb 18, 2005
Appl. No.:

11/061386
Inventors:

Carla Heise - Benicia CA, US
Sang H. Lee - Waltham MA, US
Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA
International Classification:

A01N 43/42
A61K 31/44
US Classification:

514287, 546 64
Abstract:

Methods of using compounds having Structure I or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein.

Effects Of Inhibitors Of Fgfr3 On Gene Transcription
view source
US Patent:

8158360, Apr 17, 2012
Filed:

Dec 7, 2006
Appl. No.:

12/096222
Inventors:

Carla Heise - Benicia CA, US
Esther Masih-Khan - Ontario, CA
Edward Moler - Walnut Creek CA, US
Michael Rowe - Oakland CA, US
Keith Stewart - Scottsdale AZ, US
Suzanne Trudel - Ontario, CA
Assignee:

Novartis AG - Basel
International Classification:

C12Q 1/68
G01N 33/53
US Classification:

435 614, 435 71
Abstract:

Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to FGFR3 inhibition, are measured and identifications or adjustments may be made accordingly.

Use Of Melanoma Inhibitory Activity (Mia) Protein As An Early Indicator For Therapeutic Response In Melanoma
view source
US Patent:

8288087, Oct 16, 2012
Filed:

Jul 26, 2007
Appl. No.:

12/375074
Inventors:

Nguyen Tan - San Leandro CA, US
Eleni Venetsanakos - Oakland CA, US
Michel Faure - Oakland CA, US
Carla Heise - Benicia CA, US
Assignee:

Novartis AG - Basel
International Classification:

G01N 33/48
G01N 33/50
G01N 33/53
G01N 33/574
US Classification:

435 4, 435 71, 436 64, 436813
Abstract:

The present invention provides a method for determining a response of a mammalian subject having melanoma tumor cells to treatment with a melanoma inhibitory agent. In one aspect, the method comprises (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample taken from the mammalian subject before treatment with the melanoma inhibitory agent; (b) determining a second concentration of MIA in a second biological sample from the mammalian subject taken after treatment with the melanoma inhibitory agent; and (c) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with the melanoma inhibitory agent.

Methods For Treating Drug Resistant Cancer
view source
US Patent:

8299081, Oct 30, 2012
Filed:

May 10, 2006
Appl. No.:

11/913828
Inventors:

Glenn C. Michelson - Emeryville CA, US
Vivien W. Chan - Emeryville CA, US
Carla C. Heise - Emeryville CA, US
Marion Wiesmann - Emeryville CA, US
Timothy D. Dawes - Emeryville CA, US
Assignee:

Novartis AG - Basel
International Classification:

A61K 31/497
A61K 31/535
US Classification:

51425303, 5142342, 5142305
Abstract:

A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, wherein the patient is a cancer patient with drug-resistant cancer, wherein the compound of Formula I is as defined in the application.

Benzimidazole Quinolinones And Uses Thereof
view source
US Patent:

20040092535, May 13, 2004
Filed:

Aug 19, 2003
Appl. No.:

10/644055
Inventors:

Paul Barsanti - Walnut Creek CA, US
Dirksen Bussiere - San Leandro CA, US
Stephen Harrison - Albany CA, US
Carla Heise - Benicia CA, US
Johanna Jansen - San Francisco CA, US
Elisa Jazan - Richmond CA, US
Christopher McBride - Oakland CA, US
William McCrea - Berkeley CA, US
Simon Ng - Walnut Creek CA, US
Zhi-Jie Ni - Fremont CA, US
Sabina Pecchi - Oakland CA, US
Keith Pfister - San Ramon CA, US
Savithri Ramurthy - Walnut Creek CA, US
Paul Renhowe - Danville CA, US
Cynthia Shafer - El Sobrante CA, US
Joel Silver - Concord NH, US
Allan Wagman - Belmont CA, US
Marion Wiesmann - Brisbane CA, US
Assignee:

Chiron Corporation
International Classification:

A61K031/52
A61K031/4709
US Classification:

514/263220, 514/303000, 514/312000
Abstract:

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Benzimidazole Quinolinones And Uses Thereof
view source
US Patent:

20050203101, Sep 15, 2005
Filed:

May 5, 2004
Appl. No.:

10/839793
Inventors:

Paul Barsanti - Pleasant Hill CA, US
Dirksen Bussiere - San Leandro CA, US
Stephen Harrison - Albany CA, US
Carla Heise - Benicia CA, US
Johanna Jansen - San Francisco CA, US
Elisa Jazan - Berkeley CA, US
Timothy Machajewski - Martinez CA, US
Christopher McBride - Oakland CA, US
William McCrea - Berkeley CA, US
Simon Ng - Walnut Creek CA, US
Zhi-Jie Ni - Fremont CA, US
Sabina Pecchi - Oakland CA, US
Keith Pfister - San Ramon CA, US
Savithri Ramurthy - Walnut Creek CA, US
Paul Renhowe - Danville CA, US
Cynthia Shafer - El Sobrante CA, US
Joel Silver - Santa Cruz CA, US
Allan Wagman - Belmont CA, US
Marion Wiesmann - Brisbane CA, US
Kelly Wayman - San Rafael CA, US
International Classification:

A61K031/496
C07D043/14
US Classification:

514253070, 544363000
Abstract:

Methods of treating cancer include contacting a cancer cell with 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one, 4-amino-5-fluoro-3-[5-(4-methyl-4-oxidopiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of the tautomers thereof, or a mixture thereof.

Treatment Of Metastasized Tumors
view source
US Patent:

20060183750, Aug 17, 2006
Filed:

Jan 27, 2006
Appl. No.:

11/342257
Inventors:

Daniel Menezes - Emeryville CA, US
Carla Heise - Benicia CA, US
Xiaohua Xin - Palo Alto CA, US
International Classification:

A61K 31/496
US Classification:

514253070
Abstract:

Methods of treating metastatic cancer such as metastasized tumors include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein.